Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of tipifarnib when given
together with bortezomib and to see how well they work in treating patients with relapsed
multiple myeloma. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may
kill more cancer cells.